You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
绿叶制药(02186.HK)就LY30410与东和药品在日本订立独家开发及商业化协议
阿思达克 02-18 08:25
绿叶制药(02186.HK)公布,旗下附属公司绿叶瑞士就利斯的明多日透皮贴剂(「LY30410」)与东和药品在日本订立独家许可、开发及商业化协定。

根据协定,绿叶瑞士将授予东和药品在日本开发和商业化利斯的明多天贴剂的独家权利。东和药品将在协定签署後向绿叶瑞士支付首付款,并在利斯的明多天贴剂达成若干开发、监管及销售里程碑时,向绿叶瑞士支付後续的里程碑付款。东和药品还将向绿叶瑞士支付基於利斯的明多天贴剂销售的特许权使用费。

此外,利斯的明多天贴剂在日本作为新药预计即将进入III期临床,东和药品将承担该产品在日本临床研究和注册目的有关的所有成本和费用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account